Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention

The Prostate

Volumn 17, Issue 3 S, 1990, Pages 1-7

  Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alpha1; blockers; BPH; placebo

Indexed keywords

PLACEBO;

FOLLOW UP; HUMAN; HYPERPLASIA; MALE; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; REVIEW; CONFERENCE PAPER; HISTORY; ORAL DRUG ADMINISTRATION;

FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; MALE; PLACEBOS; PROSTATIC HYPERPLASIA;

EID: 0025022904     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.2990170502     Document Type: Article

References (37)

1. Benign prostatic hyperplasia: Etiological considerations
2. Etiology and disease process of benign prostatic hyperplasia
3. Origin and evaluation of benign prostatic enlargement
4. Incidence of occult adenocarcinoma of the prostate
5. Benign hypertrophy of the prostate: A morphological study
6. Post‐natal growth changes in the human prostate
7. Benign nodular hyperplasia of the prostate: A review
8. Study of latent carcinoma of the prostate in Japanese based on necropsy material Tohoku
9. Morphogenesis of nodular hyperplasia‐prostate
10. Latent prostatic cancer in a consecutive autopsy series
11. The incidence of prostatic enlargement among 6,975 males
12. Natural history of prostatic obstruction
13. Natural history of benign prostatic hypertrophy
14. The present role of alpha‐adrenergic blockers in the treatment of benign prostatic hypertrophy
15. Natural history of benign prostatic hypertrophy
16. Development of benign prostatic hypertrophy estimated from ultrasonic measurements on patients with long‐term follow up
17. The prostate and the endocrines: A control series
18. Natural history of benign prostatic and acute urinary retention
19. The natural history of untreated “Prostatism.”
20. The powerful placebo
21. The placebo effect
22. The mechanism of placebo analgesia
23. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck
24. 1‐adrenergic receptors in human benign prostatic hyperplasia
25. Benign prostatic hypertrophy: Amino acid therapy for symptomatic relief
26. Treatment of benign prostatic hypertrophy with medrogestone
27. A double‐blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy
28. The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): A placebo‐controlled study
29. A double‐blind trial of the effects of candicidin on patients with benign prostatic hypertrophy
30. A placebo‐controlled double‐blind study of the effect of phenoxy‐benzamine in benign prostatic obstruction
31. Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy: Double‐blind study
32. Bladder outflow obstruction treated with phenoxybenz‐amine
33. Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy: A controlled study
34. Effects of prazosin in patients with benign prostatic obstruction
35. 1‐blocking drug in the treatment of bladder outflow obstruction
36. Prazosin in the treatment of prostatic obstruction: A placebo‐controlled study